{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["parsaclisib","ruxolitinib"]],"indication":"myelofibrosis","name":"LIMBER-313","nct_id":"NCT04551066","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=limber-313-nct04551066. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive parsaclisib and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.","label":"Group A : parsaclisib + ruxolitinib","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.","label":"Group B : placebo + ruxolitinib","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-11-25","type":"ACTUAL"},"conditions":["Myelofibrosis","Primary Myelofibrosis","Post Essential Thrombocythemia Myelofibrosis","Post Polycythemia Vera Myelofibrosis"],"enrollment":{"count":252,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"parsaclisib","otherNames":["INCB050465"],"type":"DRUG"},{"name":"ruxolitinib","otherNames":["Jakafi","Jakavi"],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-21","lead_sponsor":"Incyte Corporation","official_title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging [MRI] (or Computed Tomography [CT] Scan in Applicable Participants)","timeFrame":"Baseline; Week 24"}],"references":[],"start_date":{"date":"2021-05-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)","url":"https://clinicaltrials.gov/study/NCT04551066"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/limber-313-nct04551066"}